Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Consensus Rating of “Moderate Buy” from Analysts

Abeona Therapeutics Inc. (NASDAQ:ABEO) has received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $20.00.

Several equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO opened at $5.16 on Friday. The stock’s 50-day simple moving average is $5.08 and its two-hundred day simple moving average is $5.63. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.54. The firm has a market capitalization of $279.62 million, a P/E ratio of 4.20 and a beta of 1.12. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, equities analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Insider Transactions at Abeona Therapeutics

In other Abeona Therapeutics news, Director Mark Alvino sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $4.74, for a total value of $71,100.00. Following the completion of the sale, the director owned 62,252 shares of the company’s stock, valued at $295,074.48. This represents a 19.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brendan M. O’malley sold 13,578 shares of Abeona Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $72,370.74. Following the transaction, the senior vice president directly owned 451,134 shares in the company, valued at $2,404,544.22. This trade represents a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 155,576 shares of company stock valued at $818,520 over the last quarter. 6.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. raised its position in Abeona Therapeutics by 14.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after purchasing an additional 381,357 shares during the period. Vanguard Group Inc. grew its stake in shares of Abeona Therapeutics by 3.8% during the third quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock valued at $13,743,000 after buying an additional 95,878 shares during the last quarter. Boone Capital Management LLC purchased a new position in shares of Abeona Therapeutics in the second quarter worth about $7,126,000. Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 129.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after acquiring an additional 623,243 shares during the last quarter. Finally, Kennedy Capital Management LLC boosted its holdings in Abeona Therapeutics by 56.4% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock valued at $5,549,000 after acquiring an additional 378,860 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.